StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Each row shows where INSM sits in our scored universe today on a single observational measurement. P85 means INSM ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-22 | $108.47 | $106.24 | -2.06% | 2.4M |
| 05-26 | $107.82 | $108.87 | +0.97% | 2.3M |
| 05-27 | $107.80 | $106.40 | -1.30% | 3.1M |
| 05-28 | $106.90 | $108.37 | +1.38% | 2.2M |
| 05-29 | $107.85 | $106.91 | -0.87% | 4.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $305.96M | $606.42M | $342.58M | $200.24M |
Operating Income | $-153.32M | $-1.25B | $-927.02M | $-561.02M |
Net Income | $-163.56M | $-1.28B | $-948.29M | $-578.27M |
EPS (Diluted) | $-0.76 | $-6.42 | $-4.89 | $-3.12 |
Total Assets | $2.08B | $2.26B | $2.36B | $2.48B |
Total Liabilities | $1.37B | $1.53B | $1.42B | $1.23B |
Cash & Equivalents | $582.19M | $510.44M | $334.76M | $1.28B |
Free Cash Flow OCF − CapEx | $-226.22M | $-967.58M | $-703.39M | $-481.21M |
Shares Outstanding | 216.52M | 214.26M | 212.58M | 211.11M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
No sell-side coverage available for INSM yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
What drives INSM's price movement
Follow the money. Institutional flows and fund positioning are key drivers.
Mixed retail/institutional activity
Moderate volume-sensitivity
Moderate momentum sensitivity
Moderate news sensitivity
Moderate sentiment influence
Underperforming peers — laggard in sector
DNA analysis is based on current factor scoring. Not investment advice.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.